Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Accumulated Expenses: 2011-2024

Historic Accumulated Expenses for Iovance Biotherapeutics (IOVA) over the last 9 years, with Dec 2024 value amounting to $81.9 million.

  • Iovance Biotherapeutics' Accumulated Expenses was N/A to $87.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.3 million, marking a year-over-year change of. This contributed to the annual value of $81.9 million for FY2024, which is 18.05% up from last year.
  • Iovance Biotherapeutics' Accumulated Expenses amounted to $81.9 million in FY2024, which was up 18.05% from $69.4 million recorded in FY2023.
  • Iovance Biotherapeutics' 5-year Accumulated Expenses high stood at $81.9 million for FY2024, and its period low was $69.4 million during FY2023.
  • Over the past 2 years, Iovance Biotherapeutics' median Accumulated Expenses value was $75.7 million (recorded in 2023), while the average stood at $75.7 million.
  • Data for Iovance Biotherapeutics' Accumulated Expenses shows a peak YoY grew of 18.05% (in 2024) over the last 5 years.
  • Iovance Biotherapeutics' Accumulated Expenses (Yearly) stood at $69.4 million in 2023, then climbed by 18.05% to $81.9 million in 2024.